Nature Reviews Drug Discovery

Vol. 25, Issue 2 Issue 2 2026
18
Articles

Articles in this Issue

Prime editing to suppress nonsense mutations

Sarah Crunkhorn Feb 01, 2026 pp. 95-95 10.1038/d41573-026-00002-y

Promoting prostaglandin signalling for joint repair in osteoarthritis

Katie Kingwell Feb 01, 2026 pp. 94-94 10.1038/d41573-025-00209-5

2025 FDA approvals

Asher Mullard Feb 01, 2026 pp. 81-87 10.1038/d41573-026-00001-z

FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain

Asher Mullard Feb 01, 2026 pp. 88-88 10.1038/d41573-025-00207-7

Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action

Jasmine Gratton, Peter Arlett, Falk Ehmann et al. Feb 01, 2026 pp. 79-80 10.1038/d41573-025-00178-9

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety

Christopher E. Goldring, Giusy Russomanno, Carmen Pin et al. Feb 01, 2026 pp. 138-153 10.1038/s41573-025-01308-z

In vivo chimeric antigen receptor (CAR)-T cell therapy

Adrian Bot, Andrew Scharenberg, Kevin Friedman et al. Feb 01, 2026 pp. 116-137 10.1038/s41573-025-01291-5

Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities  

Alvar Agusti, Dave Singh, Rosa Faner Feb 01, 2026 pp. 98-115 10.1038/s41573-025-01290-6

Biopharma dealmaking in 2025

Patricia Giglio, Amanda Micklus Feb 01, 2026 pp. 92-93 10.1038/d41573-026-00013-9

2025 FDA approvals: volume maintained, but value remains below average

Mathias Baedeker, Clemens C. Möller Feb 01, 2026 pp. 91-91 10.1038/d41573-026-00012-w

Redirecting mast cells for antigen-specific cancer immunotherapy

M. Teresa Villanueva Feb 01, 2026 pp. 96-96 10.1038/d41573-026-00008-6

Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories

Asher Mullard Feb 01, 2026 pp. 90-90 10.1038/d41573-026-00009-5

First antibody-mimetic adnectin nabs an FDA approval

Asher Mullard Feb 01, 2026 pp. 89-89 10.1038/d41573-026-00010-y

Kinase inhibitors trigger target degradation

Sarah Crunkhorn Feb 01, 2026 pp. 97-97 10.1038/d41573-026-00004-w

Boosting CAR T cell efficacy

Sarah Crunkhorn Feb 01, 2026 pp. 97-97 10.1038/d41573-026-00005-9

Innate immune receptor agonist for cancer immunotherapy

Alex Eccleston Feb 01, 2026 pp. 94-94 10.1038/d41573-026-00003-x

Nonopioid analgesic alleviates neuropathic pain

Sarah Crunkhorn Feb 01, 2026 pp. 97-97 10.1038/d41573-026-00006-8

Histone methyltransferase inhibition hampers prostate cancer

Sarah Crunkhorn Feb 01, 2026 pp. 97-97 10.1038/d41573-026-00007-7

All Issues

Issue 7 - Issue 7 22 Issue 6 - Issue 6 20 Issue 5 - Issue 5 19 Issue 4 - Issue 4 21 Issue 3 - Issue 3 19 Issue 2 - Issue 2 18 Issue 1 - Issue 1 21
Issue 9 - Issue 9 19 Issue 8 - Issue 8 20 Issue 7 - Issue 7 21 Issue 6 - Issue 6 22 Issue 5 - Issue 5 21 Issue 4 - Issue 4 20 Issue 3 - Issue 3 19 Issue 2 - Issue 2 19 Issue 12 - Issue 12 19 Issue 11 - Issue 11 20 Issue 10 - Issue 10 21 Issue 1 - Issue 1 23

Journal Info

Publisher Springer Science and Business Media LLC
ISSN 1474-1776
E-ISSN 1474-1784
Subject Medicine
Language English
View Full Journal Page